Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Therapy – Results from C-EDGE CO-STAR Presented at The Liver Meeting® Show High Sustained Virologic Response After 12 Weeks of Treatment KENILWORTH, N.J.–(BUSINESS WIRE)–   […]

Drugmaker Gilead Sciences Inc said on Thursday the U.S. Food and Drug Administration had approved the expanded use of its blockbuster hepatitis C drug, Harvoni.   The drug can now be used to treat patients with subtypes of chronic hepatitis C virus (HCV) and patients who are co-infected with Human Immunodeficiency Virus (HIV), Gilead said […]

A massive trade pact between 12 Pacific rim countries could limit the availability of affordable medicines, the head of the World Health Organization said on Thursday, joining a heated debate on the impact of the deal.   Margaret Chan told a conference there were “some very serious concerns” about the Trans-Pacific Partnership (TPP), a central […]

NEW YORK – A team of French doctors reported Gilead Sciences, Inc. (GILD)’s blockbuster hepatitis C drug Sovaldi can cause abnormally slower heart rates in patients taking the medication. The slower heartbeats can cause patients to pass out, the doctors said in a letter to The New England Journal of Medicine. According to the French […]

Gilead Sciences Inc on Tuesday said its quarterly profit rose 70 percent, but sales growth for its hepatitis C drugs flattened as health insurers limited access to the expensive treatments. Shares of the biotechnology company fell slightly. Gilead’s quarterly product sales rose 37 percent to $8.2 billion. Sales of hepatitis C drugs Sovaldi and Harvoni […]

Teva Pharmaceutical Industries Ltd’s research chief said on Tuesday the drug industry must act responsibly when it comes to pricing medications, given the mounting anger over the high cost of therapies in the United States.   Democratic presidential candidate Hillary Clinton brought new attention to the issue last week, proposing to cap patients’ treatment costs, […]

Gilead Sciences Inc said its experimental combination treatment was effective against all forms of hepatitis C infection, citing data from four late-stage studies. The trials were evaluating a once-daily, fixed-dose combination of the drugmaker’s hep C drug, Sovaldi, with velpatasvir, an experimental NS5A inhibitor. The main goal of each study was to achieve a cure, […]